Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg says 'buy the dip' on 'top pick' Currys

(Sharecast News) - Berenberg recommended on Monday that investors 'buy the dip' in Currys, as it hailed the electricals retailer as a "top pick" for 2025. The bank said Currys' recent 15% share price fall means that it now sits around 45% below pre-Covid levels, and at similar levels to March 2020, when the pandemic first struck.

"This is despite a much stronger financial position, the run of recent upgrades and an increasingly optimistic outlook driven by self-help and structural tailwinds," it said.

"The circa 8.5x price-to-earnings gives little credit for any earnings upside and is a 48% discount to peers."

Berenberg said one can argue that the combined value of Currys' services revenue - around £700m of recurring, higher-margin, cash-generative sales - and its iD Mobile network is worth more than the current entire group market cap.

The bank said it expects its unchanged discounted cash flow-based target price of 125p to prove prudent over the medium term.

Berenberg rates Currys at 'buy'.

At 1330 GMT, the shares were up 1.5% at 87.45p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.